Renal cell carcinomaNews & Research
21 curated articles for Renal cell carcinoma — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Frontiers in immunology May 13, 2026
Adjuvant therapy for renal cell carcinoma: lessons from past failures and new opportunities in the era of immune checkpoint inhibition.
Renal cell carcinoma (RCC) has historically posed a significant therapeutic challenge in the adjuvant setting. Although surgical resection remains the cornerstone of curative-intent treatment for localized disease, a substantial proportion of patients with high-risk pathological features will experi...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Lasers in medical science Apr 20, 2026
Comparative optical characterization of renal cell carcinoma.
Accurate characterization of the optical properties of renal cell carcinoma (RCC) tissue is essential for reliable modeling of light–tissue interactions in laser-based diagnostic and therapeutic applications. In this study, the absorption coefficient (µa), scattering coefficient (µs...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Biochemical genetics Apr 16, 2026
Expression of PSTPIP1 in Renal Cell Carcinoma and Its Prognostic Value.
Renal clear cell carcinoma is the most common histological form of renal cancer, but targeted therapy is still lacking. PSTPIP1 is associated with multiple immune-related pathways and is higher expressed in tumors. Thus, the correlation of PSTPIP1 and ccRCC (clear cell renal cell carcinoma) was stud...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Cancer research and treatment Apr 16, 2026
Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study.
Adjuvant pembrolizumab improved disease-free survival (DFS) and overall survival (OS) versus placebo in participants with renal cell carcinoma (RCC) at increased risk of recurrence after nephrectomy in the global phase 3 KEYNOTE-564 study. This post hoc subgroup analysis evaluated the efficacy and s...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Cancer research Apr 15, 2026
NRF1 Induces ApoEhigh Cancer-Associated Fibroblasts to Promote Stemness of Renal Cell Carcinoma.
Cancer-associated fibroblasts (CAF) are abundant stromal cells in the tumor microenvironment (TME) that play a vital role in promoting tumor progression and drug resistance. The mechanisms regulating heterogeneity of CAFs in renal cell carcinoma (RCC) could represent potential targets for reprogramm...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Clinical and translational science Apr 15, 2026
The IQGAP1-Claudin4-JNK Signaling Axis as a Differential Biomarker in Renal Cell Carcinoma.
Renal cell carcinoma (RCC) is a highly heterogeneous malignant neoplasm with multiple morphological and molecular subtypes; however, the basis of this heterogeneity remains incompletely defined, hindering effective diagnosis and treatment. The signaling scaffold IQGAP1 and claudins are tight junctio...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Cell proliferation Apr 3, 2026
PIK-III-Mediated Elevation of Thiamine Re-Sensitises Renal Cell Carcinoma to Cuproptosis via Activating PDHA1.
Cuproptosis, a copper-dependent cell death mechanism driven by tricarboxylic acid (TCA) cycle collapse, shows limited efficacy in hypoxic or glycolytic renal cell carcinoma (RCC). Here, through systematic screening of 688 glycolysis inhibitors combined with elesclomol (ES), we identified PIK-III as ...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Current opinion in oncology Apr 1, 2026
Unclear territory: navigating metastatic nonclear cell renal cell carcinoma.
To summarize recent updates in the classification, clinical trial evidence, and evolving treatment strategies for nonclear cell renal cell carcinoma (nccRCC). The 2022 WHO classification eliminated the type 1/2 papillary paradigm, refined molecularly defined tumors such as fumarate hydratase (FH)-de...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Signal transduction and targeted therapy Apr 1, 2026
Glucocorticoids elevate clear cell renal cell carcinoma sensitivity to HIF-2α inhibitors by suppressing H4K12 lactylation.
Approximately 70% of clear cell renal cell carcinoma (ccRCC) patients harbor von Hippel‒Lindau (VHL) deficiency, which drives pseudohypoxia and metabolic reprogramming. Here, we report a histone H4 lysine 12 lactylation (H4K12la)-fueled phosphoglycerate kinase 1 (PGK1)-lactate positive feedba...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Cell death & disease Mar 31, 2026
ZDHHC9 palmitoylates LAMTOR1 to promote renal cell carcinoma malignant progression.
The lysosomal regulator complex member LAMTOR1 serves as a crucial pivot that recruits the mechanistic target of rapamycin complex 1 (mTORC1) to the lysosomal surface, thereby influencing biological processes such as cell growth and cancer progression. In renal cell carcinoma (RCC), existing studies...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Nature reviews. Urology Mar 10, 2026
Biomarkers for renal cell carcinoma - a pragmatic approach.
Biomarkers for renal cell carcinoma - a pragmatic approach.
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Molecular diversity Feb 22, 2026
Gut microbial metabolites targeting JUN in renal cell carcinoma via IL-17 signaling pathway: network pharmacology approach.
The gut microbiome plays a crucial role in renal diseases, influencing conditions such as renal cell carcinoma (RCC), acute kidney injuries, and diabetic nephropathy. Recent studies highlight the association between gut microbial metabolites (GMM) and RCC progression. This study employs a computatio...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- European urology Feb 22, 2026
CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor-based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma.
Data are limited regarding pure second-line cabozantinib use after standard first-line checkpoint inhibitor (CPI)-based combination therapy for advanced renal cell carcinoma (aRCC). We report the final results from the prospective CaboPoint study. The phase 2, multicentre, open-label CaboPoint study...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Frontiers in immunology Feb 20, 2026
Tumor-associated neutrophils in renal cell carcinoma.
Renal cell carcinoma (RCC) is an immunogenic tumor in which tumor-associated neutrophils (TANs) and neutrophil extracellular traps (NETs) represent a functionally important component of the tumor microenvironment. Recent studies have revealed pronounced phenotypic heterogeneity of RCC-infiltrating n...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Nature medicine Feb 20, 2026
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma.
Patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors or antiangiogenic tyrosine kinase inhibitors may develop resistance driven by gut dysbiosis, which disrupts the MAdCAM-1-α4β7 axis and promotes the recruitment of immunosuppressive IL-17-producing T r...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- European urology open science Feb 12, 2026
Histology-specific Prognostic Impact of Microscopic Positive Surgical Margins in Renal Cell Carcinoma: Implications for Postoperative Surveillance.
Microscopic positive surgical margins (m-PSM) have been associated with adverse outcomes after surgery in renal cell carcinoma (RCC). However, their role in survival outcomes across RCC histologies remains unclear. Our aim was to evaluate the prognostic impact of m-PSM in clear-cell RCC (ccRCC) vers...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Journal of the Chinese Medical Association : JCMA Feb 12, 2026
The evolution of renal cell carcinoma classification.
Precise classification of diseases is essential for precision medicine to develop efficient, personalized treatments for cancer. Progress in renal cell carcinoma (RCC) classification is a paradigm that demonstrates how precise classification is achieved. RCC classification has evolved from purely mo...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Journal of extracellular vesicles Feb 9, 2026
Tissue-Derived Extracellular Vesicles Define Diagnostic Biomarkers for Renal Cell Carcinoma.
Tissue-derived extracellular vesicles (Ti-EVs) play a crucial role in tumour progression, but their value as differential diagnostic markers for various renal cell carcinoma (RCC) subtypes remains uncertain. Through analysis of paired tumour and normal tissues, along with their corresponding Ti-EVs,...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Toxicology and applied pharmacology Feb 5, 2026
Cyclomulberrin represses renal cell carcinoma progression via ferroptosis activation.
Renal cell carcinoma (RCC) is one of the most common malignancies in the genitourinary system. Cyclomulberrin (CyM), a natural prenylated flavonoid, has shown anti-tumor potential. However, the efficacy and potential mechanisms of this treatment in RCC remain unclear. This study employed MTT, wound-...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Cancer Feb 3, 2026
Targeting HIF-2α in renal cell carcinoma: Expanding upon belzutifan.
Clear cell renal cell carcinoma (ccRCC) is a common subtype of kidney cancer driven by the inactivation of the von Hippel-Lindau (VHL) gene, leading to the accumulation of hypoxia-inducible factor (HIF)-2α and tumorigenesis. Targeting HIF-2α has emerged as a promising therapeutic strateg...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
- Cancer letters Jan 22, 2026
Lactic acid promotes an MDSC-like phenotype via HIF1α stabilization with impact on prognosis in renal cell carcinoma.
Paradoxically, immune cell infiltration correlates with worse prognosis in renal cell carcinoma (RCC) patients, with tumor-associated myeloid cells playing a key role in tumor progression. However, little is known about factors driving their polarization. Here, we investigated the link between RCC-r...
Why it matters: Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
More on Renal cell carcinoma
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.